Biogen's recently soaring stock price can be attributed to investor optimism in one of the most stubborn areas of drug development.
Reports that Interpublic Group may be looking to acquire US data company Acxiom's marketing solutions business for a reported $2.2bn (£1.67bn) indicates a possible doubling down on data among the agency groups, analysts at Liberum said.
Synapse executive vice president Kerry Murphy explains the struggles and triumphs of the real-world applications of data analytics.
Public trust in the pharma industry has taken a dip, according to recent data. Do actual patients agree?
Pillo's voice-activated robot will be studied among those 50-plus with diabetes. The robot uses facial recognition and can respond HIPAA-compliantly to questions.
Just after the launch of Marcel, Publicis chief executive Arthur Sadoun was bombarded with questions from a packed room of clients, staff, and journalists.
Two touted products in the pipeline reflect three of medical marketing's most profound modern-era challenges.
Medical science liaisons are essential participants in most aspects of the commercialization process.
Ogilvy is ditching Mather, introducing a new corporate identity and cementing months of streamlining with a simplified organizational structure that chief executive John Siefert says will "build a new model for our industry".
MM&M/Publicis Health's first Diversity Survey reveals some notable shifts to making the healthcare industry more inclusive, yet many agencies didn't feel like opening up about their diversity numbers.
A UK drug regulator has ruled that a 2017 press release from AstraZeneca was "misleading" as data "had not been presented in a balanced way", following a complaint from a fellow pharma firm.
If we properly and intentionally use the power of targeted marketing on behalf of our disabled customers, we might drive real value for an audience we've ignored for too long.
As of May 25, Europe's groundbreaking General Data Protection Regulation (GDPR) will take effect, fundamentally changing the way businesses and government agencies deal with personal data.
Speakers at the Coalition for Healthcare Communication conference discussed how regulations from the White House and FDA have affected healthcare comms.
Becky Chidester is CEO of Wunderman Health.
Califf spoke about the importance of more data to faster and cheaper drug development at the NewYorkBIO conference.
Croom Lawrence and Kent Groves of Merkle Health explain being human.
Opdivo's commercial potential will likely take a hit in the wake of new Keytruda data, but the impact may depend on the ability of BMS to market the message that its I-O/I-O combo allows patients to delay chemo.
David Ebersman is cofounder and CEO of Lyra Health.
Thacher Hussain is the front end developer (also WEGO Health advisory board member) at WiserCare.
William King is founder and executive chairman of Zephyr Health.
Scarlet Shore is product manager and platform lead, Project Baseline at Verily.
Justin Chase is EVP and head, innovation and media at Intouch Solutions.
Edie DeVine is SVP, U.S. director of medical and health technology at GCI Health.
Kevin Johnson is president of Marketeching.
On May 25, 2018 the European Union's General Data Protection Regulation, commonly called GDPR, will become not only the law of the land in Europe but across the globe.
Jim Boushie, director of respiratory marketing at Boehringer Ingelheim (BI) and David Laros, VP of analytics and commercial effectiveness at Aptus Health, came together to lead a joint ePharma session in March titled "Synchronized HCP and consumer campaigns: At the point of care and beyond."
With pharma facing ongoing scrutiny of its pricing practices, medical marketers are increasingly asked to demonstrate the superior value of new therapies. High-profile candidates in immunology, pain management, and melanoma challenge marketers well in advance of launch.
With healthcare evolving from a fee-for-service system toward one that bases payment on outcomes, marketers must speak to customers in value-oriented messages.
Whether it's data or marketing dollars, there should be no surprises when you partner with a company.